Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | FBRX | Common Stock | Options Exercise | $0 | +7.5K | $0.00 | 7.5K | Apr 1, 2023 | Direct | F1 | |
transaction | FBRX | Common Stock | Tax liability | -$2.62K | -2.59K | -34.57% | $1.01 | 4.91K | Apr 1, 2023 | Direct | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | FBRX | Restricted Stock Units | Options Exercise | $0 | -7.5K | -6.25% | $0.00 | 113K | Apr 1, 2023 | Common Stock | 7.5K | Direct | F1, F3 |
Id | Content |
---|---|
F1 | Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. |
F2 | On April 1, 2023, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on March 31, 2023 was the settlement price used to calculate the shares withheld. |
F3 | Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. |
President and Chief Scientific Officer